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Adeno-associated virus (AAV) is gaining momentum as a gene therapy vector for human applications.
However, there remain impediments to the development of this virus as a vector. One of these is the incomplete
understanding of the biology of the virus, including nuclear targeting of the incoming virion during initial
infection, as well as assembly of progeny virions from structural components in the nucleus. Toward this end,
we have identified four basic regions (BR) on the AAV2 capsid that represent possible nuclear localization
sequence (NLS) motifs. Mutagenesis of BR1 (120QAKKRVL126) and BR2 (140PGKKRPV146) had minor effects
on viral infectivity (4- and 10-fold, respectively), whereas BR3 (166PARKRLN172) and BR4 (307RPKRLN312)
were found to be essential for infectivity and virion assembly, respectively. Mutagenesis of BR3, which is
located in Vp1 and Vp2 capsid proteins, does not interfere with viral production or trafficking of intact AAV
capsids to the nuclear periphery but does inhibit transfer of encapsidated DNA into the nucleus. Substitution
of the canine parvovirus NLS rescued the BR3 mutant to wild-type (wt) levels, supporting the role of an AAV
NLS motif. In addition, rAAV2 containing a mutant form of BR3 in Vp1 and a wt BR3 in Vp2 was found to be
infectious, suggesting that the function of BR3 is redundant between Vp1 and Vp2 and that Vp2 may play a role
in infectivity. Mutagenesis of BR4 was found to inhibit virion assembly in the nucleus of transfected cells. This
affect was not completely due to the inefficient nuclear import of capsid subunits based on Western blot
analysis. In fact, aberrant capsid foci were observed in the cytoplasm of transfected cells, compared to the wild
type, suggesting a defect in early viral assembly or trafficking. Using three-dimensional structural analysis, the
lysine- and arginine-to-asparagine change disrupts hydrogen bonding between these basic residues and adja-
cent beta strand glutamine residues that may prevent assembly of intact virions. Taken together, these data
support that the BR4 domain is essential for virion assembly. Each BR was also found to be conserved in
serotypes 1 to 11, suggesting that these regions are significant and function similarly in each serotype. This
study establishes the importance of two BR motifs on the AAV2 capsid that are essential for infectivity and
virion assembly.
The mechanisms by which DNA viruses transfer their ge-
nomes to the nucleus can follow one of three generalized
pathways. One pathway is that the DNA is shuttled into the
nucleus by the entire virion, followed by intranuclear uncoating
of the virus and release of the viral DNA, as shown for poly-
omavirus infection (58). Another pathway leading to genome
delivery occurs when the virion is unassembled before it
reaches the nucleus, and one of the capsid proteins, or some
other viral protein, then carries the DNA to the nucleus (e.g.,
herpes simplex virus type 1 and adenovirus) (14, 39, 50, 54).
Under this scenario, a capsid component would either shuttle
the DNA into the nucleus or release the DNA at the nuclear
pore, allowing the DNA to diffuse across the membrane. A
third nuclear entry pathway, used only by some retroviruses, is
entering the nucleus during mitosis, when the nuclear mem-
brane becomes fragmented.
During the course of an adeno-associated virus (AAV) in-
fection, the capsid proteins must target the nucleus twice. The
first targeting event is during the initial infection when the
virus must deliver the viral genome to the nucleus for replica-
tion and for transcription of mRNAs that encode replication
proteins and progeny virus structural proteins. Since AAV
replicates in the nucleus of its host cell (59), the second tar-
geting event occurs when progeny viral capsid subunits enter
the nucleus for assembly into progeny virions. Despite the
importance of this critical aspect of AAV infection, very little
is known of how AAV provides for transport of its genome
across the nuclear envelope and how the progeny capsid pro-
teins gain access to the nucleus for genome encapsidation and
virion assembly. It is not known whether the virus enters the
nucleus intact and is subsequently uncoated in the nucleus or
whether the virus is uncoated in the cytoplasmic compartment.
What is known, however, is that genome entry into the nucleus
is inefficient (35, 64).
The viral capsid measures approximately 25 nm in diameter
and is composed of three proteins termed Vp1, Vp2, and Vp3,
which are translated from the same open reading frame but
from differential splicing (Vp1) and alternative translational
start sites (Vp2 and Vp3, respectively). Therefore, the capsid
proteins are identical in their C termini. Together, these pro-
teins form the viral capsid shell in a stoichiometric ratio of
1:1:10. Vp3 is the most abundant subunit in the virion and is
used for receptor recognition at the surface of cells defining
the tropism of AAV. A phospholipase domain, essential for
viral infectivity, has been identified in the unique N terminus of
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Vp1 (13, 68). The functional significance of Vp2 remains am-
biguous, but recent studies have shown that it is possible to
make viable virus lacking Vp2 in a recombinant background
(15, 57).
Surprisingly, a nuclear localization sequence (NLS) was pre-
viously identified within the Vp2 N terminus of AAV2 and was
proposed as a mediator for targeting individual capsid proteins
to the nucleus during progeny virion assembly (22). NLSs are
usually concentrated in basic residues, tend to be hydrophilic,
and are preceded by -turn/random coil regions (17, 24). NLS
regions have also been identified on other parvoviruses, such as
canine parvovirus (CPV) and minute virus of mice (MVM). It
was found that when a basic sequence representing a putative
NLS in VP1 of CPV was conjugated to bovine serum albumin
(BSA) and subsequently microinjected into HeLa cells, the
BSA localized to the nucleus (56). It was further demonstrated
that microinjection of antibodies to the basic region (BR) into
the cytoplasm of cells was sufficient to prevent subsequent
infection of the cells by CPV. The sequence identified as the
NLS of CPV was PAKRARRG, which is similar to that iden-
tified for AAV2 (PARKRLNF) (55). MVM has been shown to
contain multiple NLSs within its capsid that act at different
times during its infectious cycle (32, 33). Lombardo et al.
identified several BRs on the capsid and found that the se-
quence 528KGKLTMRAKLR538 is necessary for the localiza-
tion of the major capsid protein to the nucleus and that VP1
relies upon VP2 for cotransport across the nuclear envelope.
Once establishing the sequence necessary for the nuclear up-
take of viral capsid proteins during viral assembly, Lombardo
et al. found other BRs within the MVM capsid that conferred
infectivity upon the virus, possibly by targeting the incoming
virion to the nucleus of the target host. Interestingly, all of the
BRs identified were on the inside of the virion, indicating that
the virus must undergo some conformational change once in-
side the cell in order to complete the infection.
Although one NLS (BR3) on the Vp2 N terminus was iden-
tified by fusing truncated forms of Vp2 to green fluorescent
protein (GFP), the mechanism through which the AAV virion
gains access to the nuclear interior of its host cell remains
largely unknown. In the present study we set out to identify all
BRs within AAV’s capsid proteins that resemble NLSs. The
program P-SORT was used to search the AAV2 capsid se-
quence for NLS-like regions. Four BRs were identified and,
respectively, named BR1 through BR4, as depicted in Fig. 1A.
We illustrate here that all of the BRs affect an aspect of the
AAV life cycle. BR1 and BR2 mutants were found to play a
minor role in infectivity, inhibiting transduction 4- and 10-
fold, respectively. However, BR3 mutant capsids assembled
into intact virions but were defective for transduction in cell
lines. The BR4 motif was found to be essential for virion
assembly. A more thorough understanding of AAV’s nuclear
transport mechanisms and how they relate to classical protein
import pathways may result in a better understanding of pri-
mary steps in AAV infection that have direct impact on vector
development.
MATERIALS AND METHODS
Cell culture. HEK293 cells and HeLa cells (American Type Tissue Culture)
were maintained at 37°C in Dulbecco modified Eagle medium (Sigma) supple-
mented with 5% CO2, 10% fetal bovine serum (Sigma), 100 U of penicillin/ml,
and 100 U of streptomycin/ml.
Viral production. Confluent 293 cells were split 1:3 24 h prior to transfection.
Triple transfections with pACG2 (31), pTrufEGFP (16), and pXX6-80 (adeno-
virus helper plasmid) were carried out by calcium phosphate precipitation as
previously described (16a). At 48 h posttransfection, cells were scraped, pelleted,
and resuspended in phosphate-buffered saline (PBS). rAAV2 was purified by
using iodixanol and heparin columns as previously described (69).
Dot blot analysis for determining virus titers. The recovery of virus in terms
of genome copies was determined by DNA hybridization. A total of 10 l of each
FIG. 1. (A) Schematic of the identified BRs in the AAV capsid
gene. A description of the four mutated BRs is portrayed in the
schematic. (B) Western blot of AAV2 produced from each of the BR
mutant helper plasmids. At 24 h posttransfection, the lysates were
centrifuged through an iodixanol step gradient, followed by heparin
column purification. Approximately equal titers of purified virus were
added to each lane and detected by the B1 antibody. (C) Western blot
of the B1 and A20 immunoprecipitations from nuclear (lanes 2 to 5)
and cytoplasmic (lanes 6 and 7) fractions of pACG2-wt (lanes 1, 2, 4,
and 6) and pACG2-BR4 (lanes 3, 5, and 7) transfected 293 cells 24 h
posttransfection. Two exposures are presented (the upper exposure is
four times longer) to clearly identify capsid proteins after B1 immu-
noprecipitation in the nucleus.
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sample was incubated in 100 l of DNase I digestion buffer (10 mM Tris [pH 7.5],
10 mM MgCl2 and 50 U of DNase I/ml), followed by incubation at 37°C for 1 h.
The DNase digestion was stopped by addition of 4 l of 0.5 M EDTA. Then, 120
l of proteinase K solution (1 M NaCl, 100 g of proteinase K/ml, 1% Sarkosyl)
was added, followed by incubation at 50°C for 2 h. Next, 250 l of phenol-
chloroform was added to the digestion mixture, followed by mixing and centrif-
ugation at 16,000  g for 5 min. To precipitate viral DNA, 1 l of 20 mg of
glycogen/ml, 62.5 l of 10 M ammonium acetate, and 2.5 volumes of 100%
ethanol was added to the aqueous phase. Samples were placed on dry ice for 1 h,
followed by centrifugation at 16,000  g for 20 min to pellet the viral DNA. The
DNA pellet was then resuspended in 200 l of Tris-EDTA. After digestion with
0.5 M NaOH for 10 min, aliquots of the samples were applied to a dot blot
manifold. The denatured viral DNA was then blotted onto a nylon membrane
and probed with a 32P-labeled probe against eGFP.
Site-specific mutagenesis. Mutations to pACG2 were carried out by PCR
using the Stratagene Multi-Site-Directed Mutagenesis Kit according to manu-
facturer’s instructions. As depicted in Fig. 1, Lys123 and Arg124 in BR1, Lys143
and Arg144 in BR2, Arg168 and Lys169 in BR3, and Lys604 and Arg605 in BR4
were mutated to Asn to abrogate possible NLS functions. The plasmids express-
ing only Vp1 or only Vp3 were produced via mutagenesis of the start codons of
Vp2/Vp3- and Vp1/Vp2-expressing plasmids, respectively. Mutagenesis of the
first three start codons of Vp3 (Met 203, 211, and 235) was essential in order to
inhibit its expression Cycling parameters were as follows: 95°C for 1 min (1
cycle), 95°C for 1 min (30 cycles), 55°C for 1 min (30 cycles), and 65°C for 15 min
(30 cycles). PCR products were digested with DpnI and used to transform
electrocompetent XL10 Gold cells (Stratagene), which were then selected for
plasmid uptake by growth on ampicillin selection plates. Colonies were
picked and grown overnight in LB growth media, and plasmids isolated by
QIAGEN Miniprep kits. Mutations were verified by sequencing of the plas-
mids utilizing the UNC-CH Automated DNA Sequencing Facility on a 3100
Genetic Analyzer (Applied Biosystems). After sequence verification, each
clone was subcloned into the parent plasmid pACG2.
Immunoprecipitations. We transfected 10-cm plates as described above for
viral production. Cells were lysed 24 h later by hypotonic swelling and Dounce
homogenization in 500 l of hypotonic buffer, and the nuclei were separated
from the cytoplasmic supernatant by centrifugation. The cytoplasmic fraction
was made isotonic with 0.11 volumes of 1 M Tris-buffered saline (TBS) and
centrifuged at 10,000  g to clear the sample of cytoplasmic debris. The nuclear
pellet was washed several times to prevent cytoplasmic protein contamination
before resuspension in 100 l of high-salt buffer, drawn several times through a
small-bore needle, and centrifuged at 10,000  g to clear the sample of nuclear
debris. The sample was brought to 500 l by the addition of 1 TBS. A total of
40 l of either B1 or A20 hybridoma supernatant was added to the samples, and
the samples were tumbled overnight at 4°C. Then, 40 l of protein A/G beads was
added to the samples, and the beads were collected by centrifugation at 500  g.
Beads were washed three times in radioimmunoprecipitation assay buffer and then
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western
blotting for the analysis of capsid proteins as described below.
Western blotting. Samples from cell homogenate and purified vector were
loaded onto NuPage 10% Bis-Tris gels and run using 1 NuPage MOPS buffer.
The XCell SureLock Mini Cell (Invitrogen) was used for electrophoresis. Protein
was then transferred to a Hybond ECL membrane utilizing the XCell II Blot
module (Invitrogen) for wet transfer according to the manufacturer’s protocol
for Bis-Tris gels. Each membrane was blocked for 1 h at room temperature using
1 TBS (pH 7.5), 0.1% Tween, and 10% nonfat dry milk (NFDM). The primary
B1 antibody was then diluted 1:10 in 1 TBS (pH 7.5), 0.1% Tween, and 2%
NFDM, followed by incubation on the membrane for 1 h at room temperature
or overnight at 4°C. Excess primary antibody was then washed from the mem-
brane using 1 TBS (pH 7.5)–0.1% Tween four times for 5 min each time.
Secondary antibody was then diluted 1:10,000 in 1 TBS (pH 7.5), 0.1% Tween,
and 2% NFDM, followed by incubation on the membrane for 1 h at room
temperature. Excess secondary was then washed from the membrane as previ-
ously described. SuperSignal West Femto Maximum Sensitivity Substrate
(Pierce) was then added to each membrane according to the manufacturer’s
protocol. Each membrane was then exposed to Kodak BioMax MR film.
Transduction experiments. Transduction experiments were carried out utiliz-
ing HeLa cells. To keep consistency throughout experiments in the study, HeLa
cells were infected with 3,000 viral genomes/cell. Transduction of HeLa cells
was assayed by utilizing a fluorescence microscope at 48 h postinfection.
Immunohistochemistry by TSA. Immunohistochemistry was performed by
tyramide system amplification (TSA; Perkin-Elmer) according to manufacturer’s
instructions with modifications. HeLa cells were seeded onto two-chamber glass
slides at 5  104 cells/well. After 24 h, cells were infected with 3,000 physical
particles per cell at 4°C for 1 h, washed, and placed at 37°C. After the indicated
amount of time, the cells were fixed and permeabilized in 100% methanol at
20°C for 10 min and then washed three times for 5 min each time in room
temperature PBS. Cells were blocked in TSA blocking buffer for 1 h at room
temperature. Cells were then incubated with monoclonal antibody (MAb) B1
diluted 1:200 in PBS-Tween (PBS-T; PBS with 0.05% Tween). Cells were washed
in PBS-T three times for 5 min each time and incubated for 1 h with the
secondary antibody (horseradish peroxidase-conjugated rabbit anti-mouse anti-
body; Sigma) diluted 1:5,000 in PBS-T. Cells were again washed three times for
5 min each time in PBS-T, incubated for 10 min in Tyramide-Cy3 labeling
solution, and washed three times for 5 min each time in PBS-T (in light-protected
Coplin jar). Two drops of antifade mounting media containing DAPI (4,6-
diamidino-2-phenylindole; Vecta Shield) was placed on the slide, and a slide
cover was sealed onto the slide with nail polish. Slides were imaged immediately
by confocal microscopy on a Leica SP2 scanning confocal microscope capable of
differential interference contrast overlay.
Fluorescence in situ hybridization by TSA. Fluorescent in situ hybridization
was carried out by TSA in accordance with the manufacturer’s instructions with
modifications (Perkin-Elmer). HeLa cells were seeded onto two-chambered
slides at a density of 5  104 cells/well. The cells were infected 24 h later by
3,000 AAV2 particles/cell (or mutants of AAV2) as described above (4°C for
1 h, followed by washing with PBS, and placement at 37°C). After the indicated
incubation times, cells were washed four times with PBS and fixed in cold
methanol-acetic acid (3:1) for 5 min at 20°C. Cells were then washed three
times for 5 min each time in PBS. Dehydration of the cells was carried out by
2-min incubations in each of 70% ethanol at 20°C, 90% ethanol at room
temperature, and 100% ethanol at room temperature. Slides were then treated
with protease at 100 g/ml in PBS for 60 min at 37°C and again dehydrated as
described above. Cells were then incubated in 50% formamide–2SSC (1 SSC
is 0.15 M NaCl plus 0.015 M sodium citrate) for 5 min at 72°C.
Preparation of DNA probe. GFP gene DNA was labeled with biotin (Boerhinger
Biotin NT) according to the manufacturer’s instructions. The probe solution was
made with 10 ng of biotinylated DNA/l, 15 ng of salmon sperm DNA/l, 50%
formamide, 7% dextran sulfate, and 0.75 SSC. Probe solution was boiled for 10
min and placed onto the cells, and the cells were covered with slide covers and
then sealed with rubber cement. Incubation of the cells with the biotinylated
probe was carried out overnight at 37°C. After overnight incubation, cells were
washed three times for 5 min each time in 50% formamide–2 SSC at 42°C and
then washed in PBS-T three times for 5 min each time. Streptavidin-horseradish
peroxidase was diluted 1:100 in PBS-T and placed on the cells. Cells were then
washed three times for 5 min each time in PBS-T and incubated for 30 min in
Tyramide-Cy3 labeling solution. Cells were washed three times for 5 min each
time in PBS-T. Two drops of Vecta Shield antifade mounting media was placed
on each slide, the cells were covered with a coverslip, and the coverslip was
sealed to the slide with rubber cement. Visualization of the sample was carried
out on a Leica SP2 scanning confocal microscope.
Confocal immunofluorescence. HeLa cells were seeded at a density of 3  104
cells per well for each slide (Nalge Nunc International Lab-Tek II eight-well RS
glass slide). HeLa cells were then infected with 300 viral genomes of wild-type
AAV2 (wtAAV2)/cell and an adenovirus multiplicity of infection (MOI) of 5 or
transfected with 130 ng of XX680, 100 ng of pACG2 or pACG2-BR4, and 65
ng of TR plasmid cytomegalovirus-luciferase and incubated for 24, 18, and 12 h.
Cells were then washed three times with 1 PBS, followed by fixing in 1:1
methanol-acetone at room temperature for 5 min. The slides were then air dried
briefly and then rehydrated with 1 PBS with 1.5 mM MgCl2 at room temper-
ature for 5 min. The rehydrated cells were then washed two times for 5 min in
immunofluorescence (IF) wash buffer (20 mM Tris-HCl [pH 7.6], 137 mM NaCl,
3 mM KCl, 1.5 mM MgCl2, 5 mg of BSA/ml, and 0.05% Tween 20). Primary
antibody B1 (1:10) and anti-fibrillarin (1:100) was diluted in IF wash buffer and
incubated for 1 h at 37°C. Cells were then washed with IF wash buffer several
times for 15 min at room temperature. Secondary anti-mouse (Alexa-Fluor 488)
and anti-rabbit (Alexa-Fluor 568) antibodies (Molecular Probes) were then di-
luted 1:1,000 in IF wash buffer and incubated on the cells for 1 h at 37°C. The
cells were then washed as previously described, and mounting media containing
DAPI was added to each slide. Samples were viewed on Leica SP2 aobs confocal
microscope.
Luciferase assay. Assays of luciferase activity were carried out in accor-
dance with the manufacturer’s instructions (Promega), without modification.
The luciferase activity was measured by a Tropix TR717 automated plate
reader.
VOL. 80, 2006 SEPARATE AAV2 CAPSID PROTEIN BASIC REGION MOTIFS 5201
RESULTS
Initial characterization of the BRs within the AAV2 capsid.
The program P-SORT was used to search the AAV2 capsid
sequence for areas concentrated in basic residues. Four re-
gions were identified and named BR1 through BR4 as depicted
in Fig. 1A. To establish whether each BR is critical to the life
cycle of AAV2, mutagenesis of two of the basic residues in
each region to asparagines was carried out as described in
Materials and Methods. Basic arginine and lysine residues
were replaced with polar and neutral asparagine residues
rather than with hydrophobic alanine residues to guarantee
that each of the mutagenized BRs had a similar hydropathy to
wt while inhibiting possible NLS activity (12, 33, 47). It has
been shown in a previous alanine scanning mutagenesis study
on the AAV2 capsid that mutagenesis of BR1 to -3 negatively
affected infectivity (2 to 3 logs) (62). However, in our study
BR1 and BR2 were not found to affect infectivity by 2 to 3 logs
but 4- to 10-fold, and we believe this is due to substituting
asparagines into each BR as opposed to alanines, which is a
more dramatic residue change. As an initial step in character-
izing the mutants, we produced recombinant virus by using the
previously described pACG2 helper plasmid and assayed for par-
ticle titer (ability to protect its viral genome from DNase diges-
tion) and for infectivity (the ability of AAV to deliver the eGFP
transgene to the nucleus). All of the experiments carried out here
were repeated several times to ensure confidence in the data. It is
important to note that the data described here concurs with un-
published data (from the laboratory of Jurgen Kleinschmidt as
presented at the International Parvovirus Meeting, 2004).
From these analyses, we defined three phenotypes that fell into
three classes. Class 1 mutants produced DNase-resistant particle
titers similar to that of rAAV assembled from wt capsids with the
correct subunit ratio (Fig. 1B) but transduced cultured HeLa cells
less efficiently than wt (data not shown). AAV2-BR1 and
AAV2-BR2 could be categorized as class 1 mutants in that they
transduced cells 4- and 10-fold less efficiently than the wt, respec-
tively. A similar study using a different amino acid substitution
resulted in a more severe phenotype (62). However, using an
amino acid substitution that specifically disrupts potential NLS
activity without major changes to hydropathy suggests that these
regions do not play the primary role in AAV infectivity in vitro
and are not involved in capsid subunit transport into the nucleus
for assembly. Class 2 mutants produced DNase-resistant particle
titers similar to recombinant virus made from wt capsid proteins
but were defective at transducing cultured HeLa cells (Fig. 2B).
AAV2-BR3 were class 2 mutants. Finally, class 3 mutants did
not yield intact vector particles. AAV2-BR4 were class 3. Upon
further analysis, we found that the BR4 mutation inhibited cap-
sid assembly in the nucleus but did not affect nuclear import of
capsid subunits (Fig. 1C, lanes 3 and 5).
BR3 plays a role in virion infectivity. The BR3 sequence was
previously proposed as a mediator for targeting individual cap-
sid proteins to the nucleus during progeny virion assembly
(22). In these experiments, the authors constructed a fusion
protein with Vp2 and GFP. The fusion protein localized pri-
marily to the nucleus, but when N-terminal deletions were
made to VP2, a BR (denoted BR3 in our study) was found to
be necessary for localizing the fusion protein to the nucleus.
The authors concluded that Vp2 is necessary for nuclear trans-
fer of the capsid proteins prior to virion assembly. Our data
suggest that BR3 is not necessary for the accumulation of
capsid proteins during virion production but is instead re-
quired for initial virion nuclear targeting and infectivity (Fig.
2). To help support this divergence in the role of BR3 in the
AAV life cycle, we carried out additional studies with intact
virions carrying the BR3 mutant. Since this virus has wt hep-
arin sulfate (HS) binding activity and can compete for HS
binding (data not shown), we determined whether this mutant
virus was capable of competing with wt capsids for trafficking
events subsequent to initial viral binding to the cell surface.
For example, it has been suggested that AAV is internalized
into endosomes at a ratio of 1 viral particle per endosome (49).
However, it is unlikely that the endosomes containing AAV
traffic all of the way to the nucleus without merging with other
AAV-containing endosomes, since endosomal merging is part
of the normal endosome trafficking mechanism in mammalian
cells (30). To test this aspect of AAV trafficking, wt capsids
with a luciferase transgene (AAV2-Luc) were allowed to bind
HeLa cells at 4°C, followed by the addition of wtAAV2-GFP or
AAV2-BR3-GFP to the cell supernatant, and warmed to
37°C, and the luciferase activity was measured 12 h later.
wtAAV2-GFP and AAV2-BR3-GFP competed with the
wtAAV2-Luc at a step subsequent to receptor binding and, in
turn, reduced the expression of the wtAAV2-Luc by more than
50% (data not shown). In addition to determining that AAV2-
BR3 would compete with wtAAV trafficking, we asked the
FIG. 2. Fluorescence microscopy images of AAV2, AAV2-BR3-GFP, and coinfection with AAV2-luciferase for a complementation study.
HeLa cells were infected with 3,000 viral genomes/cell of AAV2-GFP (A) or AAV2-BR3-GFP (B) and coinfected with AAV2-BR3-GFP and
AAV2-Luc (C). Positive cells express GFP. Images were obtained with a Leitz DMIL fluorescence microscope.
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reciprocal question: could wtAAV particles facilitate AAV2-
BR3 productive infection and rescue the mutant phenotype?
We reasoned that if transduction by the AAV2-BR3 virus
was blocked by an inability of the virus to carry out a specific
trafficking step (i.e., endosome escape), maybe coinfection
with nondefective virions would allow the AAV2-BR3-GFP
to transduce cells. HeLa cells in culture were infected simul-
taneously with AAV2-Luc and AAV2-BR3-GFP and assayed
48 h later by fluorescence microscopy for GFP expression.
Figure 2C depicts that coinfection of HeLa cells with AAV2-
Luc and AAV2-BR3-GFP does not rescue the infectivity of
the BR3 mutant virus. Based on the present understanding of
AAV infection, these data suggest that the mutation may affect
a trafficking step downstream of endosome escape.
Tracking AAV2-BR3 mutant via confocal microscopy. Pre-
vious methods of detecting AAV capsid proteins in tissue cul-
ture cells required MOIs of 1 million virions per cell. We
established a protocol through which only 1,000 to 5,000 par-
ticles are needed per cell to image the capsid proteins by
immunohistochemistry, since 1 million particles per cell (and
perhaps even 5,000 particles per cell) is in excess of physiolog-
ical levels. We optimized the TSA (Bio-Rad) protocol for
detecting AAV capsid proteins in HeLa cells cultured in cham-
bered glass slides (see Materials and Methods) and viewed the
capsid proteins by confocal microscopy. The HeLa cells were
infected for 24 h with 3,000 viral genomes of wtAAV2-GFP or
AAV2-BR3-GFP per cell, processed for TSA-based immu-
nohistochemistry, and assayed by confocal fluorescence mi-
croscopy. The location of AAV capsid proteins for both
AAV2-GFP and AAV2-BR3-GFP (red staining) utilizing the
B1 antibody shows capsid proteins accumulating in the perinu-
clear region (Fig. 3Ai and ii) similar to published data (1, 35,
64). Therefore, AAV2-BR3-GFP was internalized normally
FIG. 3. Confocal microscopy images of the subcellular localization of AAV2 and AAV2-BR3 capsid proteins (A) or fluorescent in situ
hybridization against the GFP gene after infection of HeLa cells (B). HeLa cells were grown in chambered glass slides and infected with either
AAV2-GFP (i) or AAV2-BR3-GFP (ii). Cells were processed 24 h later for immunohistochemistry with the MAb B1 and fluorescence in situ
hybridization for the GFP genomes. The samples were then processed by using TSA. (B) Two cells were selected from a population of cells to
illustrate the low concentration (left panels) and high concentration (right panels) of GFP genomes in the nucleus. The red staining represents
capsid protein (A) and GFP genomes (B).
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and accumulated at the nuclear periphery similarly to
wtAAV2-GFP.
Once we established that AAV2-BR3 traffics to the nuclear
periphery similarly to AAV2, we sought to determine whether
the associated viral genome entered the nucleus. HeLa cells
were infected with AAV2-GFP or AAV2-BR3-GFP and pro-
cessed 24 h later for fluorescence in situ hybridization for the
incoming GFP genome. Cells were then examined by con-
focal microscopy to determine the location of the GFP gene
delivered by the incoming virions. Clear punctate staining
can be seen inside the nucleus for wtAAV2-GFP-infected cells
(Fig.3Bi), with the majority of the viral genomes located in a
rim around the nucleus, as was previously shown for the capsid
proteins (Fig. 3A) (1, 35, 64). However, a majority of the
staining for the GFP gene, delivered by the BR3 vector, was
located around the perimeter of the nucleus with very little, if
any, GFP genomes in the nucleus (Fig.3Bii). These data
strongly suggest that the AAV2-BR3 mutant is incapable of
delivering its genome into the nucleus with an efficiency similar
to wtAAV2 capsids and provide a working explanation for the
inability of this mutant virion to transduce target cells.
Use of a heterologous NLS to rescue infectivity. Although
the studies described above support the role of NLS activity for
BR3, substitution experiments with a known NLS motif were
carried out to further establish this hypothesis. PCR site-di-
rected mutagenesis was used to replace the BR3 mutation in
pACG2-BR3 with the nuclear localization motif (NLS) iden-
tified for CPV, PAKRARR (55, 56). Figure 4 shows HeLa cells
24 h postinfection with wtAAV2-GFP (Fig. 4A), AAV2-BR3-
GFP (Fig. 4B), or AAV2-CPVNLS-GFP (Fig. 4C). Substitu-
tion of the NLS of CPV restored infectivity to the AAV2-
BR3-GFP mutant as shown by the GFP-expressing cells in
panel C. The NLS identified within CPV was capable of sub-
stituting the function provided by the AAV2 putative NLS
(BR3), providing independent evidence that the primary role
of BR3 is transport of viral genomes, not capsid subunits as
previously proposed (22), to the nucleus.
BR3 is functional in both Vp1 and Vp2 capsid proteins.
Since AAV2 BR3 is located in both Vp1 and in Vp2 and a
previously published study has suggested that Vp2 is dispens-
able (57), we sought to determine whether the function pro-
vided by BR3 is derived solely from Vp1 or Vp2. Previously,
the ability to express AAV capsid proteins using separate
helper plasmids has allowed one to systematically determine
the role of each subunit in AAV infection (57). Toward this
end, we produced virions composed of Vp3 only, Vp1/Vp3,
Vp1BR3/Vp3, Vp2/Vp3, and Vp1BR3/Vp2/Vp3 packaging
the GFP transgene. HeLa cells were infected with 3,000 viral
genomes/cell of each vector both in the presence (Fig. 5A) and
in the absence (data not shown) of adenovirus (MOI of 5).
Infectivity was assessed by fluorescence microscopy to identify
GFP fluorescing cells. As previously described (13, 45), Vp3
only and Vp2/Vp3 virions were not infectious (Fig. 5Aii and
5Aiii) due to the lack of the phospholipase domain. Upon the
addition of wtVp1, the Vp1/Vp3 and Vp1/Vp2/Vp3 viruses
were found to be infectious (Fig. 5Aiv and v). However, sub-
stitution of wtVp1 with Vp1BR3 (Vp1BR3/Vp3) resulted in
noninfectious virions (Fig.5Avi). The phospholipase domain of
Vp1BR3 is functional based on in vitro assay (data not
shown), supporting the premise that BR3 plays a primary role
in virion transport to the nucleus. To further illustrate this
point, AAV2 virions composed of wtVp2, wtVp3, and mutant
Vp1 (Vp1BR3) were infectious (Fig.5Avii). Vp1BR3/Vp2/
Vp3 infectious virions supports the premise that functional
phospholipase activity is contributed by the mutant Vp1 sub-
unit (Vp1BR3) and further suggests that the redundant BR3
domain on Vp2 is also functional, allowing the transport of
viral genomes into the nucleus. Similar GFP transduction data
were collected in the presence or absence of Ad, suggesting
that the trafficking helper functions of Ad (64) do not aid in
BR3 genome import into the nucleus compared to the wt.
Previous studies have suggested that the role of Vp2 is un-
known and dispensable (57). Our data support the potential
for the BR3 region in either Vp1 or Vp2 or both to facilitate
nuclear transport of incoming virions/viral genomes into the
nucleus. It has been previously identified that Vp1 N termini
can become surface exposed when capsids are heated, suggest-
ing that this may be mimicking what is happening within the
cell to expose the phospholipase domain of Vp1 (2, 4). Figure
5B adds to the previous studies by showing (utilizing MAb A69
specific to Vp2 N terminus) that the N termini of Vp2 can also
become surface exposed on the virion (composed of Vp2/Vp3)
after a mild heat treatment. This suggests that when the nec-
essary capsid conformational change occurs within the cell,
Vp2 N termini may also become surface exposed, aiding in
infectivity.
BR4 may be a region in the capsid subunit that is important
for virion assembly. As depicted in Fig. 1A, BR4 is located in
the Vp3 coding region. When this region is mutagenized,
DNase-resistant particles are not detected by dot blot hybrid-
ization, suggesting that capsids are not assembled. After ob-
taining this result, we carried out additional studies to help
determine the underlying defect of BR4 in AAV infection. We
fractionated transfected 293 cells into nuclear and cytoplasmic
FIG. 4. Fluorescence microscopy images of AAV2-infected HeLa cells. Substitution of the canine parvovirus NLS for the BR3 mutant
sequence rescues transduction. HeLa cells were infected with 3,000 viral genomes/cell of AAV2-GFP (A), AAV2-BR3-GFP (B), and AAV2-
CPVNLS-GFP (C). Positive cells express GFP. Images were obtained with a Leitz DMIL fluorescence microscope.
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fractions at 24 h posttransfection and immunoprecipitated
them with B1 and A20 antibodies that recognize unassembled
and assembled capsids, respectively. Based on Western blot
analysis, capsid proteins were immunoprecipitated from the
cytoplasm and nuclear fractions for both wt and BR4 mutants
(Fig. 1C, lanes 4 to 7). However, assembled capsids were only
detected from the nucleus with wt capsid subunits after A20
immunoprecipitation (Fig. 1C, lanes 2 and 3). Altogether,
these data suggest that BR4 capsid proteins are produced at
concentrations similar to those for wt and are able to access the
nucleus but do not assemble into intact virions.
Previous studies have established that AAV2 assembles in
the nucleus in “intranuclear assembly centers” that increase in
size over time as more capsid proteins enter and virions are
assembled (23, 59, 60). It has been suggested that the assembly
centers occur within nucleoli (59). A number of other viruses
or viral components have been shown to interact with the
nucleolus and its components, supporting the logic for this
observation (10, 21, 34, 36–38, 42, 63). With this evidence in
hand, we set up an immunofluorescence study to determine
whether intranuclear assembly centers form in the nuclei of
pACG2-BR4-transfected HeLa cells. HeLa cells were coin-
fected with wtAAV2 and adenovirus as a control, along with
independent transfections of wt AAV2 plasmid pACG2 and
pACG2-BR4, as described in Materials and Methods. Cells
were fixed and probed with the B1 antibody and fibrillarin
antibody (specific for nucleoli). The results from this analysis
established that intranuclear assembly centers are present in
wtAAV2-infected cells, as previously described (23, 59, 60),
along with wt and mutant BR4 transfected cells (Fig. 6A, C,
and E). DAPI staining was carried out on all samples to con-
firm the nuclear location of the assembly centers (Fig. 6B, D,
and F). However, similar foci were also detected in the cyto-
plasm of pACG2-BR4 transfected cells (Fig. 6E, white boxed
regions), suggesting that mutagenesis of this region affects the
localization of capsid subunits. Further analysis of the BR4
mutation with respect to the crystal structure of AAV2 sug-
gests potential destabilization of the capsid subunit structure
by abrogating essential hydrogen bonding from the adjacent
beta strand that might lead to possible precipitation in the
cytoplasm.
DISCUSSION
Successful infection by AAV is a multipart process involving
specific interaction of the virion at the surface of the cell, entry
via an endocytic pathway, and escape from this compartment
into the cytoplasm from which the viral genome is delivered to
the nucleus of the cell (5). Specific domains on and within the
capsid are necessary to carry out the infectious process, includ-
FIG. 5. (A) Fluorescence microscopy images of HeLa cells infected
with assorted AAV2 virions in the presence of adenovirus at an MOI
of 5. HeLa cells were infected with AAV2 (i), Vp3 only (ii), Vp2/Vp3
(iii), Vp1/Vp2/Vp3 (iv), Vp1/Vp3 (v), Vp1BR3/Vp3 (vi), and
Vp1BR3/Vp2/Vp3 (vii) GFP viruses at 3,000 viral genomes/cell to
determine whether the redundant BR3 sequence on Vp2 is functional.
AAV2 was produced from a single helper plasmid supplying all three
capsid proteins. The Vp2/Vp3 virus was produced from the Vp2/Vp3
expressing plasmid. The Vp1 only, Vp1BR3 only, and Vp3 only
expressing plasmids were produced for the present study by mutating
the start codons of Vp2/Vp3 and Vp1/Vp2, respectively. These plas-
mids were then utilized together and in combination with the Vp2/Vp3
plasmid to produce the Vp1/Vp2/Vp3, Vp1BR3/Vp2/Vp3, Vp1/Vp3,
and Vp1BR3/Vp3 viruses. (B) A native dot blot assay of wtAAV2
and Vp2/Vp3 virions. Each virus was heated to 60°C for 5 min and then
reacted with A20 (intact capsids), B1 (unassembled capsids), A1 (Vp1
N termini), or A69 (Vp1 and Vp2 N termini) under nondenaturing
conditions.
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ing domains essential for receptor binding and internalization,
endosome escape, and nuclear transport (1, 27, 40, 64). At
present, little is known about the later steps in the AAV in-
fection pathway. From the limited studies to date, a discrep-
ancy regarding these steps exists, and recent studies suggest
that trafficking can be a function of the cell type studied (1,
7–9, 18–20, 48, 49, 64). We set out here to delineate BRs
(typically associated with NLS activity) on the AAV capsid that
are essential for viral infectivity and nuclear accumulation of
capsid proteins for virion assembly. Four BRs representing
potential NLS domains were identified in the capsid of AAV2
and mutagenized to determine their respective roles in the life
cycle of AAV2. AAV2 with mutated forms of each BR were
assessed for their ability to produce virus, incorporate all three
capsid proteins within the virion at wt ratios, and transduce
cells and were assayed for capsid protein distribution in cells
actively producing the virus (BR4). We show that BR3 and
BR4, as depicted in Fig. 1A, were essential for viral infectivity
and capsid assembly, respectively.
A nuclear targeting sequence is essential for AAV infection.
The size of the AAV capsid is 25 nm, which is close to the
functional capacity limit of the nuclear pore complex (11).
Therefore, AAV could potentially enter the nucleus via the
NPC as an intact particle. It is unknown whether AAV enters
the nucleus intact or disassembles perinuclearly. Evidence sup-
porting both possibilities has been uncovered (1, 35, 48, 64).
Based on structural studies, the putative NLS region (BR3) is
located within the virion on the N terminus of Vp2 and Vp1
and therefore could not be used by an incoming virion to
interact with the NPC transport machinery unless conforma-
tional changes took place first (28, 29, 61, 65). However, the
data from our study suggest that the BR3 sequence is necessary
for AAV2 to deliver its genome within the nucleus and subse-
quently transduce the cells (Fig. 3, 5, 6, and 7). A working
model for how autonomous parvoviruses resolve this concern
has been established, and most likely is mimicked to some
degree by AAV. Specifically, it has been shown that MVM and
CPV virions expose their NLS-containing Vp1 N termini in
vitro upon exposure to mild heating or low pH without disas-
sembly, mimicking what might be occurring within the cell,
presumably in the endosome (3, 4, 46, 51, 56). Two recent
studies have shown that Vp1 is located within the AAV virion
(2, 28). We show in the present study that Vp2 is also exposed
after mild heating (Fig. 5B). Thus, the AAV capsid must un-
dergo a certain degree of conformational change or partial
disassembly during intracellular trafficking to the nucleus, lead-
ing to the exposure of the N-terminal 172 amino acids of Vp1
and/or the N-terminal 35 amino acids of Vp2, exposing the
FIG. 6. Immunofluorescence and confocal microscopy images of HeLa cells infected with wtAAV2 and transfected with pACG2 and pACG2-
BR4. Panels A through F were analyzed by indirect immunofluorescence using a Leitz DMIL fluorescence microscope. Panel G is an overlay
image that was analyzed by confocal microscopy using the Leica SP2 aobs confocal microscope. HeLa cells were infected with wtAAV2 and
adenovirus (A and B), transfected with pACG2 and adenovirus helper plasmid XX680 (C and D), and transfected with pACG2-BR4 (E and F)
and adenovirus helper plasmid. Each sample was probed with primary antibodies B1 (anti-capsid subunits) and fibrillarin (nucleolar protein).
Capsid proteins are identified by green fluorescence (Alexa-Fluor 488 secondary) (A, C, and E), fibrillarin is identified by red fluorescence
(Alexa-Fluor 568) (G), and nuclei are identified by blue fluorescence (DAPI) (B, D, F, and G). A series of horizontal sections (each 0.3 m) were
obtained for panel G. The white arrow points to intranuclear assembly centers identified by the B1 antibody. GFP exposure times were identical
for panels C and E, while a shorter exposure time was used for panel B due to increased abundance of capsid protein in the cells.
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BR3 domain (Fig. 5B). The availability of BR3 would then aid
in nuclear targeting of the incoming virion.
The BR3 sequence represents a region on the capsid impor-
tant for AAV2 infectivity and is functional on Vp1 and Vp2
capsid proteins. As described earlier, the BR3 sequence was
previously proposed as a mediator for targeting individual cap-
sid proteins to the nucleus during progeny virion assembly, and
this transport was facilitated by Vp2 (22). This conclusion does
not seem to be likely or the sole function based on the facts
that the Vp2 concentration is much lower (ca. 10- to 20-fold)
than Vp3 and that previous studies have demonstrated the
ability to produce Vp3 only particles at or near wt levels (data
not shown) (57). In the present study, we analyzed BR3 in the
context of the virus and found it to be essential for AAV2
infectivity (Fig. 2, 3, 4, and 5A) but not necessary for the
localization of capsid proteins to the nucleus during viral as-
sembly (Fig. 1B). Substitution of the BR3 sequence with the
NLS identified for CPV, PAKRARR (55, 56), was found to
confer NLS function in the context of the rAAV2 virion, add-
ing further support that this basic amino acid region located in
Vp1 and Vp2 is essential for primary infection (Fig. 4). It will
be of interest to determine whether BR3 interacts with any
known nuclear transport factors or acts solely as an NLS for
virion nuclear transport.
In accordance with identifying the role of BR3 as the NLS
important for infectivity, we sought to determine whether the
function of the BR3 sequence, which resides in both Vp1 and
Vp2, is redundant between these two capsid proteins. To ad-
dress this concern, we produced rAAV2 composed of single
components or combinations of capsid subunits (Vp3 only,
Vp1/Vp3, Vp1BR3/Vp3, Vp2/Vp3, and Vp1BR3/Vp2/Vp3)
encapsidating the eGFP transgene. As illustrated in Fig. 5A,
we demonstrated a requirement for Vp2BR3 in a virion back-
ground lacking this motif in Vp1. This virion combination was
infectious, suggesting that the BR3 sequence on Vp2 is also
functional and redundant to the BR3 provided by Vp1 in wt
virions. Consistent with our mutant combination virion studies,
our in vitro heating data suggest that the N terminus of Vp2
can be exposed in a manner similar to that of Vp1, supporting
a role for Vp2 in the infectious pathway (Fig. 5B).
The BR4 domain may play a role in virion assembly. Our
initial studies done on each of the BR mutants illustrated that
BR4 did not produce intact particles but was capable of
producing capsid subunits that accessed the nucleus (Fig. 1C),
localizing in intranuclear assembly centers (Fig. 6E and F) (32,
33). It is noteworthy to mention that two studies have sug-
gested that AAV virion assembly occurs in nucleoli utilizing
indirect immunofluorescence for nucleolin (44) and an unspec-
ified nucleolar protein (59). However, utilizing confocal mi-
croscopy (Fig. 6G and data not shown), the intranuclear as-
sembly centers do not colocalize with nucleoli (based on the
fibrillarin staining), suggesting that these capsid assembly cen-
ters are distinct from nucleoli as previously described (23a). In
line with this, two studies have shown that adenovirus is capa-
ble of redistributing nucleolar proteins such as nucleolin, B23,
and fibrillarin to other regions of the cell, including the cyto-
plasm (37, 41). Adenovirus coinfection was used in all of the
AAV subcellular localization studies, including the present
study, suggesting that this result may be an artifact of adeno-
virus in the cell.
The present study also revealed that the BR4 capsid pro-
teins were produced at levels similar to those of the wt capsid
proteins and accumulated in the nucleus and cytoplasm simi-
larly to wt (Fig. 1C). However, intact particles were not de-
tected in the nucleus of pACG2-BR4 transfected cells, which
is in contrast to pACG2-wt transfected cells (Fig. 1C, lanes 2
and 3). Based on these data, the linear motif of BR4 does not
seem to be the domain essential for subunit entry into the
nucleus or important for localizing capsid subunits into the
intranuclear assembly centers. However, if similar to autono-
mous parvovirus (MVM), a conformational/structural (three-
dimensional) NLS, formed from capsid subunit interactions,
may be essential to access to the nucleus for assembly. In fact,
further analysis into the crystal structure of AAV2 suggests
that mutagenesis of residues K309 and R310 to asparagine may
destabilize the structure of the capsid subunit and may not
be involved in capsid subunit nuclear import (M. Agbandje-
McKenna, unpublished data) as depicted in Fig. 7B. These two
residues are located in beta strand D, which is a core structural
motif that is located within the capsid of parvoviruses. K309
and R310 directly interact (through hydrogen bonding) with
E683 and E685, respectively, in the adjacent beta strand I.
Changing K309 and R310 to asparagines disrupts these inter-
actions. This premise is supported by an independent study
showing a similar phenotype when E683 and E685 were mu-
tated to alanine (62). These two independent studies show
similar results, which suggests a possible trafficking defect or
defect in intersubunit interactions as a consequence of mis-
folding.
Infectious entry pathway of AAV2. Figure 7 is a schematic
representation of the infectious entry pathway of AAV2 based
on previous studies and in conjunction with the data described
here. The early steps of AAV2 infection begin with attachment
to a variety of cell surface receptors, such as HSPG, FGFR,
	v5 integrin, and hepatocyte growth factor receptor (c-Met)
(Fig. 7, step 1) (6, 26, 43, 52, 53) followed by clathrin-mediated
endocytosis (Fig. 7 step 2). Based on a number of studies, it has
been proposed that AAV requires endosomal acidification to
escape from the late endosome and traffic to the nucleus (Fig.
7, steps 3 and 4) (7, 19, 66, 67). The data based on autonomous
parvoviruses suggest that, prior to escaping the endosome, the
virion undergoes conformational changes, leading to the expo-
sure of the N terminus of Vp1, which is necessary for escape
(Fig. 7, step 3) (3, 46). However, based on endosomal pH
studies on CPV infection, the exposure of Vp1 may not be the
only factor involved in escape from the endosome (51). Our
data suggest that BR3, located 172 amino acids in Vp1 and 35
amino acids in Vp2, must also be exposed (Fig. 5B) at some
point in the infectious pathway, presumably the endosome, for
a successful infection to occur (Fig. 7, step 3 image enhanced).
It was determined that AAV capsids are ubiquitinated, mark-
ing them for degradation by the proteasome (Fig. 7, step 5)
(66). In support of this, the use of proteasome inhibitors such
as MG-132 and LLnL has been shown to increase transduc-
tion, providing evidence that, after endosome escape, AAV
must elude cytoplasmic proteasomes while trafficking to the
nucleus (Fig. 7, steps 4 and 5) (7, 67) or facilitating down-
stream steps such as uncoating or gene expression, etc. It
remains unclear whether the entry of intact AAV2 into the
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nucleus occurs or whether uncoating occurs before or during
nuclear entry (35, 64).
We have shown that the putative NLS of AAV2, identified
by Hoque et al. and termed BR3 here, is not solely necessary
to mediate the nuclear accumulation of capsid proteins for
nuclear assembly but is important in the translocation of the
AAV2 genome across the nuclear envelope during primary
infection. We suggest that BR3 is a putative NLS necessary for
AAV infection. The BR3 domain is also conserved among
AAV serotypes 1 through 11 (Table 1), suggesting that each
serotype accesses the nucleus utilizing a similar NLS. The
Vp1/Vp2-specific BR3 sequence is similar to consensus se-
quences that bind karyopherin 	 and  receptors (24, 25),
suggesting that AAV may use components of this transport
pathway to bind or dock their genomes to the NPC in associ-
FIG. 7. (A) Schematic representation of the infectious entry pathway of AAV2 (step 1). The first step in AAV2 infection is binding to its
primary receptor and a secondary receptor (step 2). AAV2 enters the cell by endocytosis via clathrin-coated pits and is brought into the cytoplasm
in an early endosome (step 3). The early endosome then matures into a late endosome as the pH begins to drop to around 5. A pH-dependent
conformational change occurs that is thought to expose the N terminus of Vp1, and possibly BR3, providing the phospholipase activity for
endosome escape and region essential for genome import into the nucleus (step 4). At this point in the pathway, AAV either fails to escape the
late endosome, where it later becomes degraded by the lysosome or escapes into the cytoplasm perinuclearly, where it becomes ubiquitinated (step
5). The ubiquitinated virions can then be recognized by cytoplasmic proteasomes on their way to the nucleus, where they are degraded, but those
that avoid interaction with the proteasomes continue on their path to the nucleus (step 5). (B) Schematic representation of the pathway involved
in AAV2 capsid protein synthesis and assembly of wt capsid proteins and those containing the BR4 mutation. AAV DNA is found in the nucleus
of transfected cells, and mRNA is produced and translated into the capsid proteins, which shuttle into the nucleus for assembly. The red capsid
proteins represent wt capsid sequence, while the blue proteins represent the capsid proteins with the BR4 mutations (depicted in yellow). The wt
capsid subunits are capable of intersubunit interactions, leading to the intermediate pentamer/trimer formation, leading to capsid assembly. We
propose that the misfolded/destabilized BR4 capsid subunits are incapable of intersubunit interactions and cannot form intact virions.
TABLE 1. Sequences of AAV serotypes 1 to 11
AAV
Sequence
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ation with Vp1 and/or Vp2. Numerous different forms of 	 and
 importins exist in eukaryotic cells (in different concentra-
tions), suggesting that different isoforms could bind particular
target proteins. Substitution of the CPV NLS for BR3 in
AAV2 was able to carry out a successful infection, implying
that it may be possible to substitute well-characterized NLSs
for BR3 to enhance transduction in a cell-specific manner. This
study also suggests that Vp2 may play a role in the life cycle of
AAV, and this function may be most evident in vivo such as
enhancing transduction. It is clear that a better understanding
of AAV biology, such as the role of NLS domains, holds
promise for improving AAV vectors by modifying capsid struc-
ture to obtain virion infectivity with desired traits (i.e., efficient
trafficking, enhanced nuclear targeting, and/or timely release
of vector template in the nucleus).
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